Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
KDR, Active(K01-11G)

KDR, Active(K01-11G)

  • $226.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human KDR (789-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :789-end

Genbank Number :NM_002253

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay, Western Blot

Molecular Weight :~110 kDa

Gene Aliases :FLK1; VEGFR; VEGFR2

Scientific Background :KDR (or kinase insert domain receptor) is a growth factor receptor tyrosine kinase that was originally isolated from human endothelial cells where it plays a pivotal role in endothelial cell proliferation and differentiation. KDR and its mouse homolog Flk1 bind VEGF with high affinity and are implicated in the development of new blood vessels (angiogenesis) (1). The expression levels of VEGF and KDR are highly correlated during the normal development of the ocular vasculature in humans (1). Induction of angiogenesis is a critical step in tumor progression, and inhibitors of KDR have been demonstrated both to induce tumor regression and reduce metastatic potential in preclinical models (2).

References :
1. Neufeld, G. et al: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999 Jan;13(1):9-22.

2. Zhu, Z. et al: Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs. 1999;17(3):195-212.

Product Sheets (By Lot #) :

H068-1.pdf

M093-2.pdf

A1194-4.pdf

C2043-7.pdf

Research Areas :Cancer, Inflammation, Cardiovascular Disease, AKT/PKB Pathway, ERK/MAPK Pathway, p38 Pathway, Apoptosis/Autophagy, Angiogenesis, Receptor Tyrosine Kinases, Cancer, Inflammation, Cardiovascular Disease, AKT/PKB Pathway, ERK/MAPK Pathway, p38 Pathway, Apoptosis/Autophagy, Angiogenesis, Receptor Tyrosine Kinases